Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients
JA Kobashigawa, JD Moriguchi, H Laks… - The Journal of heart and …, 2005 - Elsevier
BACKGROUND: Outcomes from this trial's first year data demonstrated significant benefit in
heart transplant patients treated with pravastatin in cholesterol levels, survival, rejection with
hemodynamic compromise, the development of cardiac allograft vasculopathy, and
decreased natural killer cell cytotoxicity. Other heart transplant studies have shown similar
benefit. We now report the 10-year follow-up of this study. METHODS: Ninety-seven heart
transplant recipients were randomized to pravastatin (n= 47) or no pravastatin (n= 50) within …
heart transplant patients treated with pravastatin in cholesterol levels, survival, rejection with
hemodynamic compromise, the development of cardiac allograft vasculopathy, and
decreased natural killer cell cytotoxicity. Other heart transplant studies have shown similar
benefit. We now report the 10-year follow-up of this study. METHODS: Ninety-seven heart
transplant recipients were randomized to pravastatin (n= 47) or no pravastatin (n= 50) within …